Skip to main content

Richard Bender

Signal Genetics has appointed Richard Bender its chief medical officer, effective Sept. 14. He will report directly to Signal President and CEO Samuel Riccitelli. 

Bender has more than 30 years of experience in clinical oncology/hematology and medical diagnostics. Most recently, he consulted for various companies and was a long-term medical affairs consultant for Quest Diagnostics. Previous to that, he was vice president and CMO at Agendia, and before that, he was the medical director of hematology/oncology at Quest in San Juan Capistrano, California. He also held management positions at Johnson & Johnson Pharmaceutical and at Permanente Medical Group.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.